Company Performance Metrics
- Patric Stenberg: Co-Founder and CEO
Gesynta Pharma is a clinical stage pharmaceutical company, developing a portfolio of compounds which inhibit the pro-inflammatory enzyme mPGES-1. Gesynta Pharma's research originates from Karolinska Institutet.
The company's most advanced drug candidate is vipoglanstat (GS-248), in clinical Phase 2 development as a non-hormonal treatment
for endometriosis. In an advanced preclinical disease model of endometriosis, vipoglanstat significantly reduced the number of endometriotic lesions characterizing the disease. Additionally, the study showed distinct pain relief and improved well-being. Clinical studies of vipoglanstat have demonstrated a favorable safety profile and excellent pharmacological properties. Endometriosis is a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age, making it one of the most prevalent conditions in the field of women's health. Endometriosis often leads to severely reduced quality of life and currently available therapeutic options are inadequate for many patients.
The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023 for another inflammatory condition.
Gesynta Pharma was founded in 2017 and is based in Stockholm. The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors.
